Relmada says independent analysis shows depression treatment unlikely to meet main trial goal
04/12/2024 12:42
Dec 4 (Reuters) - Relmada Therapeutics RLMD.O said on Wednesday its treatment for a major depressive disorder is "unlikely" to meet the main goal of a late-stage trial, according to an independent data monitoring committee's analysis. (Reporting by Christy Santhosh in Bengaluru) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Relmada Therapeutics
See all newsRelmada Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Relmada Therapeutics Q2 EPS USD -0.11
Relmada Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia As Chief Business Officer
Brief: Relmada Therapeutics - Increases Authorized Common Stock To 200 Million Shares From 150 Million